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HIV-1 subtype AFunctional studies of HIV-1 envelope glycoproteins (Envs) commonly include the generation of
pseudoviruses, which are produced by co-transfection of rev–vpu–env cassettes with an env-deﬁcient
provirus. Here, we describe six Env constructs from transmitted/founder HIV-1 that were defective in the
pseudotyping assay, although two produced infectious virions when expressed from their cognate
proviruses. All of these constructs exhibited an unusual gene arrangement in which the ﬁrst exon of rev
(rev1) and vpu were in the same reading frame without an intervening stop codon. Disruption of the rev1–
vpu fusion gene by frameshift mutation, stop codon, or abrogation of the rev initiation codon restored
pseudovirion infectivity. Introduction of the fusion gene into wildtype Env cassettes severely compromised
their function. The defect was not due to altered env and rev transcription or a dominant negative effect of
the expressed fusion protein, but seemed to be caused by inefﬁcient translation at the env initiation codon.
Although the rev1–vpu polymorphism affects Env expression only in vitro, it can cause problems in studies
requiring Env complementation, such as analyses of co-receptor usage and neutralization properties, since
3% of subtype A, 20% of subtype C and 5% of CRF01_A/E viruses encode the fusion gene. A solution is to
eliminate the rev initiation codon when amplifying rev–vpu–env cassettes since this increases Env
expression irrespective of the presence of the polymorphism.
© 2009 Elsevier Inc. All rights reserved.Introduction
The envelope glycoprotein (Env) of Human Immunodeﬁciency Virus
Type 1 (HIV-1) is essential for virus transmission and replication, and
thus a prime target of drug and vaccine development efforts (Wyatt and
Sodroski, 1998; Zwick and Burton, 2007; Kwong and Wilson, 2009).
Because Env is packaged into virus particles when expressed in trans,
Env function is frequently assessed in the context of pseudovirions,
which are produced when an HIV-1 env expression vector is co-
transfected with an env-deﬁcient proviral backbone (Helseth et al.,
1990; Gao et al., 1996; Binley et al., 2004; Beddows et al., 2005; Provine
et al., 2009).Most Envexpressionvectors contain rev–vpu–env cassettes,
because the presence of rev sequences has been reported to enhancerogram, Science Applications
r Institute-Frederick, Frederick
ll rights reserved.glycoprotein expression and particle incorporation (Hammarskjold et
al., 1989; Lu et al., 1990; Kammler et al., 2001). The biological activity of
Env complemented pseudovirions is characterized in single round
infectivity assays utilizing cells that express high levels of CD4, CCR5 and
other receptor molecules (Whitcomb et al., 2007; Keele et al., 2008;
Nedellec et al., 2009). Pseudotyping is sensitive, quantitative, repro-
ducible and suitable for high through-put analyses (Whitcomb et al.,
2007, Monteﬁori et al., 2007). Thus, this approach is widely used to
determine the coreceptor usage, entry properties and neutralization
phenotype of circulating HIV-1 strains (Richman et al., 2003;Whitcomb
et al., 2007; Nedellec et al., 2009; Isaacman-Beck et al., 2009).
Pseudotyping has also been implemented to standardize the neutral-
izingantibody response of newcandidateHIV-1 vaccines (Mascola et al.,
2005; Li et al., 2005; Li et al., 2006; Monteﬁori et al., 2007).
Most existing Env expression cassettes have been generated by bulk
polymerase chain reaction (PCR) ampliﬁcation of viral nucleic acids
from infected patient blood or tissue, followed by cloning of the
respective amplicons into an appropriate expression vector (Binley
et al., 2004; Li et al., 2005; Li et al., 2006). Some investigators have also
347M.H. Kraus et al. / Virology 397 (2010) 346–357explored the utility of linear env expression cassettes (containing bulk
PCR amplicons ligated downstream of a CMV promoter), which do not
require interim cloning (Kirchherr et al., 2007; Beels et al., 2008).
Although these approaches have yielded numerous functional Env
expression vectors, not all generated constructswere biologically active.
This is not unexpected since a substantial fraction of HIV-1 sequences in
vivo is defective (Goodenow et al., 1989;Munoz et al., 1993). Moreover,
bulk PCR is known to generate in vitro artifacts since it does not preclude
Taq-polymerase induced nucleotide substitutions and template switch-
ing (Shriner et al., 2004; Palmer et al., 2005; Salazar-Gonzalez et al.,
2008). Thus, when Env expression cassettes are identiﬁed that yield
poorly infectious pseudovirions, they are assumed to encode defective
env genes and excluded from further analysis.
Dissecting the molecular mechanisms underlying HIV/SIV trans-
mission, we have recently developed an experimental strategy that
permits the identiﬁcation, enumeration and molecular cloning of
transmitted/founder viruses (Keele et al., 2008). This strategy, which
uses single genome ampliﬁcation (SGA) of plasma viral RNA or cell-
associated proviral DNA followed bydirect amplicon sequencing, allowsFig. 1. Identiﬁcation of transmitted/founder Envs that are defective in the pseudotyping assa
pZM247Fv1, pZM247Fv2 and pZM246F-10 and their corresponding rev–vpu–env cassettes. R
2009); rev (solid), vpu (shaded) and env (hatched) coding sequences are highlighted. (B
infectious units (IU) per nanogram (ng) of p24 antigen (y-axis). (C) Replication kinetics of
cells. HIV-1 reference strains NL4.3 and YU2 were included for control (x-axis: days pos
replication kinetics were observed in CD4+ T cells from two additional human donors.inference of the nucleotide sequence of the particular viral strains that
established the productive infection (Salazar-Gonzalez et al., 2008;
Keele et al., 2009; Salazar-Gonzalez et al., 2009, Abrahams et al., 2009;
Lee et al., 2009). An important corollary of this approach is that
transmitted/founder viruses must be fully functional and encode all
proteins necessary for transmission. Indeed, biological characterization
of an initial set of 55 subtype B transmitted/founder Envs revealed that
all of them, without exception, mediated efﬁcient virus entry in the
pseudotyping assay (Keele et al., 2008). Subsequent derivation of full-
length transmitted/founder genomes further supported this paradigm:
each of 12 transmitted/founder proviral clones produced replication
competent virus that grew to high titers in primary humanCD4+T cells
(Salazar-Gonzalez et al., 2009; Ochsenbauer-Jambor et al., 2009).
To generate a comprehensive panel of genetically diverse transmit-
ted/founder Env expression cassettes,we recently characterized samples
frompatients acutely infectedwithHIV-1 subtype C (Salazar-Gonzalez et
al., 2008; Abrahams et al., 2009). Sequences spanning the entire rev, vpu
and env genes were ampliﬁed from plasma viral RNA, shown to conform
to model predictions of random viral evolution, and used to infer they. (A) Genomic organization of transmitted/founder infectious molecular clones (IMCs)
estriction enzyme sites used for IMC construction are indicated (Salazar-Gonzalez et al.,
) Infectivity of Env complemented pseudovirions in the JC53-BL assay, expressed as
ZM247Fv1, ZM247Fv2 and ZM246F-10 transmitted/founder viruses in human CD4+ T
t-infection; y-axis: nanogram of p24 antigen per ml of culture supernatant). Similar
Fig. 2. Protein composition of Env complemented pseudovirions. Pseudovirions derived
by cotransfection of SG3Δenv with the indicated Env constructs were puriﬁed,
equilibrated by reverse transcriptase (RT) activity (150 ng RT/lane), and subjected to
Western blot analysis using plasma from a patient chronically infected with HIV-1
subtype C. Bands corresponding to envelope (gp160, gp120, gp41), RT (p66 and p51),
integrase (p32), capsid (p24) and matrix (p17) proteins are indicated.
Table 1
Infectivity of Env trans complemented pseudovirions.
Infectious titer
(IU/ml)a
p24 activity
(ng/ml)b
Virion infectivity
(IU/ng p24)
ZM247Fv1ΔEnvc 33 3,589 0
ZM246F IMCd 313,000 140 2,236
ZM246F Enve 3,583,000 1,346 2,662
ZM247Fv1 IMCd 2,393,000 1,603 1,493
ZM247Fv1 Enve 144,000 1,154 125
a Determined as the number of β-galactosidase-expressing JC53-BL cells per ml of
transfection supernatant.
b Nanograms of p24 capsid protein per ml of transfection supernatant.
c Env-deﬁcient proviral backbone used for trans complementation.
d Infectious molecular clone.
e Env construct used for trans complementation.
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Abrahams et al., 2009). A subset of these cassettes was then cloned,
conﬁrmed tomatch the transmitted/founder sequences, and functionally
tested in the pseudotyping assay. Surprisingly, these analyses identiﬁed
six transmitted/founder Env cassettes that were defective in the
complementation assay. Moreover, two of these seemingly defective
Envcassettesproduced fully replication competentviruswhenexpressed
from their cognate proviruses (Salazar-Gonzalez et al., 2009). These
results thus indicated that Env cassettes that encoded fully functional env
genes could appear defective in the pseudotyping assay.
In this paper, we have investigated themechanisms responsible for
this unusual phenotype. We show that all complementation defective
rev–vpu–env cassettes tested contain a polymorphism upstream of env
in the intergenic region between the ﬁrst exon of rev (rev1) and vpu.
This polymorphism places rev1 and vpu into the same reading frame
without an intervening stop codon. The resulting rev1–vpu fusion gene
does not impair the replication potential and infectivity of full-length
genomes; however, its presence suppresses Env translation from
subgenomic rev–vpu–env transcripts. This ﬁnding reinforces the
concept that transmitted/founder viruses are fully functional and
outlines a new strategy to search for novel Env phenotypes.
Results
Identiﬁcation of transmitted/founder Env cassettes that are defective in
the pseudotyping assay
We recently cloned a panel of transmitted/founder HIV-1
genomes and showed that all of them encoded viruses that were
fully replication competent (Salazar-Gonzalez et al., 2009; Ochsen-
bauer-Jambor et al., 2009). Since three of these infectious molecular
clones (IMCs) represented members of HIV-1 subtype C (pZM246F-
10, pZM247Fv1 and pZM246Fv2), we selected their rev–vpu–env
cassettes for inclusion into a panel of genetically diverse Env
expression vectors (Fig. 1A). ZM246F-10 was derived from a patient
infected with a single donor variant, while ZM247Fv1 and ZM247Fv2
were derived from a subject infected with two donor variants
(Salazar-Gonzalez et al., 2008). Surprisingly, only one of the three
rev–vpu–env cassettes was capable of complementing Env in trans
(Fig. 1B). Co-transfection of ZM246F Env with the env-deﬁcient
subtype B backbone SG3Δenv yielded pseudovirions that were highly
infectious in the JC53-BL single round infectivity assay (Derdeyn et al.,
2000; Wei et al., 2002). In contrast, cotransfection of ZM247Fv1 and
ZM247Fv2 Env cassettes with the same backbone produced viral
stocks that exhibited only a minimal level of infectivity (Fig. 1B).
These phenotypic differences were highly reproducible and not due to
inadvertent sequencing or cloning artifacts (not shown). Moreover,
repeat analysis of the corresponding IMCs conﬁrmed that all of them
replicated efﬁciently in human CD4+ T cells with kinetics similar to
HIV-1 reference strains (Fig. 1C).
To investigate these phenotypic differences, we examined the
protein composition of the Env trans complemented pseudovirions.
293T cells were co-transfected with various expression plasmids
(ZM246F Env, ZM247Fv1 Env, SG3 Env, or no Env for control) and the
SG3Δenv backbone, and the resulting particles examined by immu-
noblot analysis using plasma from a patient infected with HIV-1
subtype C. As shown in Fig. 2, particles complemented with ZM246F
Env and the positive SG3 Env control contained large amounts of
extracellular (gp120) and membrane bound (gp41) envelope glyco-
proteins. They also contained considerable quantities of the uncleaved
Env precursor (gp160), which is a characteristic feature of pseudo-
viruses (Provine et al., 2009). In contrast, ZM247Fv1 Env comple-
mented particles exhibited only a faint gp160 band and no detectable
gp120 or gp41 bands, indicating little to no functional Env
incorporation. Immunoblot analysis of ZM247Fv2 Env complemented
virions yielded similar results (not shown).Generation of an env-deﬁcient proviral backbone of HIV-1 subtype C
Since the trans complementation experiments described above
utilized an env-deﬁcient subtype B vector (SG3Δenv), we considered
the possibility that the defective phenotypes of ZM247Fv1 and
ZM247Fv2 Envs were due, at least in part, to an incompatibility with
the proviral backbone. We thus used site-directed mutagenesis to
abrogate Env expression from the ZM247Fv1 IMC. Trans complemen-
tation experiments conﬁrmed the utility of this new vector (Table 1).
Co-transfection of ZM247Fv1Δenv with ZM246F Env yielded virions
thatwere highly infectious in JC53-BL cells (2662 IU/ng p24), reaching
titers similar to the corresponding IMC (2236 IU/ng p24). However,
co-transfection of ZM247Fv1Δenvwith the cognate ZM247Fv1 Env did
not restore its biological activity (125 IU/ng p24), thus excluding
backbone incompatibility as the reason for the defective phenotype.
Since ZM247Fv1Δenv consistently produced 2- to 6-fold higher titer
virus stocks than SG3Δenv when co-transfected with subtype C Env
constructs (not shown), we used this backbone for all further trans
complementation experiments.
Defective Env expression cassettes exhibit an unusual gene arrangement
Since ZM247Fv1 and ZM247Fv2 transmitted/founder viruses
encoded fully functional env genes (Fig. 1C), and since backbone
incompatibility could not explain the pseudotyping results (Table 1),
Fig. 3. Gene arrangement in rev–vpu–env cassettes. (A) ZM247Fv1 and ZM247Fv2 Env
cassettes contain the ﬁrst exon of rev (rev1) and vpu in the same reading frame without
an intervening translational stop codon (broken lines). A single nucleotide deletion (Δ)
in the intergenic region between rev1 and vpu generated a clone (ZM247Fv1-fs) with a
more common gene arrangement present in most HIV-1 strains. (B) Infectivity of
ZM247Fv1 and ZM247Fv1-fs Env complemented pseudovirions compared to the
corresponding IMC (y-axis, infectious units (IU) per nanogram (ng) of p24).
Fig. 4. Transcriptional proﬁle of ZM247Fv1 and ZM247Fv1-fs Env expression cassettes.
(A) Expression constructs and predicted transcripts (highlighted in blue). The
cytomegalovirus promoter/enhancer (CMV), the bovine growth hormone polyadeny-
lation signal (pA), and the HIV-1 rev splice donor (SD4) and acceptor (SA7) sites are
shown. (B) Northern blot of 293T cells transfected with the indicated Env cassettes, in
the absence (left panel) and presence of a rev expression vector (right panel). A
digoxigenin-labeled antisense cRNA speciﬁc for ZM247Fv1 rev2 was used for high-
stringency hybridization. The migration of 18 S and 28 S ribosomal RNA markers is
shown.
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functional Env expression cassettes. This revealed a unique polymor-
phism between the ﬁrst exon of rev (rev1) and vpu in ZM247Fv1 and
ZM247Fv2 that was absent from ZM246F. This polymorphism placed
rev1 and vpu into the same reading frame without an intervening stop
codon, thereby generating a rev1–vpu fusion gene (Fig. 3A). To
determine whether this gene arrangement was responsible for the
defective phenotype, we introduced a frameshift mutation into the
ZM247Fv1 rev–vpu–env cassette by deleting a single nucleotide in the
intergenic region between rev1 and vpu (Fig. 3A). Wildtype
(ZM247Fv1) and frameshift mutant (ZM247Fv1-fs) Envs were
cotransfected with the ZM247Fv1ΔEnv proviral backbone and the
infectious titer of the resulting pseudovirions determined. As shown
in Fig. 3B, separation of rev1 and vpu into different reading frames was
sufﬁcient to restore the infectivity of ZM247Fv1-fs Env complemented
virions to IMC levels.
The rev1–vpu polymorphism does not appear to alter RNA transcription,
stability or splicing
To determine whether the rev1–vpu polymorphism reduced RNA
synthesis or altered the splicing patterns of subgenomic messages, we
compared the transcriptional proﬁle of 293T cells transfected with
ZM247Fv1 and ZM247Fv1-fs Env cassettes (Fig. 4). Cells were
transfected with these plasmids alone and together with a rev
expression vector (pZM247Fv1rev). Rev (regulator of expression of
viral proteins) is essential for Env expression since it binds to Rev
Response Element (RRE)-containing unspliced and partially spliced
HIV-1 mRNAs, facilitating their transport from the nucleus to thecytoplasm (Malim et al., 1988; Malim and Emerman, 2008).
Consequently, we examined RNA transcription both in the presence
and absence of this trans complemented protein (Fig. 4A). Total RNA
was extracted from transfected cells and hybridized to a cRNA
antisense probe speciﬁc for the second exon of rev (rev2). The
resulting Northern blots revealed no differences in the amounts of
full-length and spliced transcripts in the presence or absence of trans
complemented Rev (Fig. 4B). Cells transfected with ZM247Fv1 and
ZM247Fv1-fs produced equivalent levels of rev–vpu–env (3.6 kb) and
rev (1.3 kb) mRNAs at steady state (Fig. 4B, left panel). The rev
transcript appeared to be spliced as predicted utilizing known splice
donor (SD4) and acceptor (SA7) sites (Purcell and Martin, 1993).
Similar amounts of unspliced and spliced mRNAs were also observed
in cells co-transfected with the rev expression vector, which produced
an additional smaller rev transcript of 0.7 kb (Fig. 4B, right panel).
Thus, the rev1–vpu polymorphism did not appear to reduce the
Fig. 5. Site-directed mutagenesis of ZM247Fv1 and ZM246F Env cassettes. Nucleotide and deduced amino acid sequences are shown for the intergenic region between the ﬁrst exon
of rev (blue) and vpu (green). Mutations are highlighted in magenta, with deletions indicated by periods and insertions by lower case letters. Dashes represent gaps introduced to
optimize the alignment. The rev intron splice donor SD4 is underlined. A schematic representation of rev1 and vpu gene arrangement is shown on the right, with “Xs” indicating
substitutions of the respective initiation codons, and an asterisk depicting an in-frame stop codon.
350 M.H. Kraus et al. / Virology 397 (2010) 346–357abundance or stability of full-length rev–vpu–env transcripts, or alter
the ratio of unspliced to spliced messages.
The rev1–vpu polymorphism reduces Env expression from rev–vpu–env
cassettes
To elucidate the mechanisms underlying the complementation
defect, we generated additional ZM247Fv1 and ZM246F rev1–vpu
mutants (Fig. 5). These included constructs in which translation of the
ZM247Fv1 rev and/or vpu genes was abrogated by mutation of their
initiation codons (ZM247Fv1-Rev−, ZM247Fv1-Vpu−, ZM247Fv1-Rev
−Vpu−) as well as a construct in which the ZM247Fv1 rev1 and vpu
genes were separated by an in-frame stop codon (ZM247Fv1-stop).
We also introduced a frameshift mutation into the intergenic region
between the rev1 and vpu genes of ZM246F to generate a fusion gene
in the context of a functional Env expression vector (ZM246F-fs).
Mutant and wildtype constructs were co-transfected with the
ZM247Fv1ΔEnv backbone, and the infectious titers of the resulting
pseudovirions determined in JC53-BL cells (Fig. 6A). In addition, Env
expression and virion incorporation was examined by immunoblot
analysis (Fig. 6A). These experiments revealed that all mutations that
disrupted the rev1–vpu fusion gene (ZM247Fv1-fs, ZM247Fv1-stop,
ZM247Fv1-Rev−, ZM247Fv1-Rev−Vpu−) restored Env complemen-
tation and resulted in pseudovirions with markedly increased Env
content. Conversely, placement of a rev1–vpu fusion gene into an
otherwise functional Env cassette (ZM246F-fs) abrogated Env
complementation and generated pseudovirions with greatly dimin-
ished Env content. Linear regression analysis showed that Env
(gp120) content and pseudovirion infectivity were signiﬁcantly
correlated (Fig. 6B), indicating that the pseudotyping defect was
caused by a lack of Env in the trans complemented virus particles.
However, this was not due to a packaging defect, but a reduction of
Env expression in transfected cells. These data thus established the
rev1–vpu polymorphism as the primary cause of the pseudotyping
defect and identiﬁed diminished Env expression from fusion gene
containing rev–vpu–env cassettes as the underlying mechanism.
Interestingly, not all rev1–vpu fusion gene containing Env cassettes
were completely defective in the pseudotyping assay. As shown in Fig.
6A (lane 6), pseudovirions complemented with ZM247Fv1-Vpu− Env,
a construct that lacked the vpu initiation codon but contained anintact rev1–vpu fusion gene (Fig. 5), were partially infectious and
containedmore gp120 than pseudotypes generatedwith the wildtype
ZM247Fv1 Env construct (lane 3). Thus, removal of the vpu initiation
codon increased Env expression irrespective of the presence of a
rev1–vpu fusion gene.
Fusion gene containing Env cassettes express a Rev1–Vpu protein
We next asked whether fusion gene-containing rev–vpu–env
cassettes expressed a Rev1–Vpu protein and whether production of
such a protein suppressed Env expression. To accomplish this, we
ﬁrst generated antibodies capable of detecting subtype C Vpu by
expressing the cytoplasmic domain of the ZM247Fv1 Vpu protein in
bacteria and immunizing rabbits with the recombinant protein. The
resulting polyclonal antibodies were then used to probe 293T cell
lysates that were co-transfected with the various Env cassettes as
well as pZM247Fv1rev to supply Rev in trans. The same cell lysates
were also probed with anti-gp120 antibodies to assess Env
expression (Fig. 7, middle panel), as well as antibodies speciﬁc for
a vector-encoded protein (neomycin phosphotransferase II) to
control for transfection efﬁciency (Fig. 7, bottom panel). The results
revealed that all Env cassettes that contained a rev1–vpu fusion gene
(i.e., ZM247Fv1, ZM247Fv1–Vpu− and ZM246F-fs) expressed a
Rev1-Vpu protein product of expected molecular weight (14 kDa
for ZM247Fv1 and ZM247Fv1-Vpu−; 14.5 kDa for ZM246F-fs).
Interestingly, ZM247Fv1 and ZM246F-fs Envs also expressed a
regular Vpu protein (12 kDa and 13 kDa, respectively), indicating
that both Rev1–Vpu and Vpu were translated from the same cistron
(Fig. 7, top panel). Env constructs, in which Rev1–Vpu expression
was abrogated by frameshift mutation (ZM247Fv1-fs), in-frame stop
codon (ZM247Fv1-stop), or mutation of the rev initiation codon
(ZM247Fv1-Rev–) expressed only wildtype Vpu, while the double
mutant (ZM247Fv1-Rev−Vpu−) expressed no Vpu-reactive protein.
Interestingly, these latter constructs produced signiﬁcantly more
gp160/120 glycoprotein than Env cassettes that expressed the
Rev1–Vpu protein (Fig. 7, middle panel). Quantitative Western blot
analysis indicated that ZM247Fv1 and ZM246F-fs Env cassettes
yielded the least amounts of gp160/gp120, while ZM247Fv1–Vpu−
Env produced only slightly more of these glycoproteins (not shown).
Thus, Env expression was markedly diminished from fusion gene
Fig. 6. Env expression and pseudovirus infectivity. (A) Single round infectivity values
(IU/ng p24) of trans complemented pseudovirions (top panel) are shown in relation to
Env expression (middle panel) and particle incorporation (bottom panel). Infectious
titers were averaged from two different experiments (mean and standard error are
shown). Cell lysates (20 μg) and pelleted virus particles (100 ng particle-associated RT
activity) were probed with anti-gp120 and anti-p24 speciﬁc antibodies. (B)
Relationship between pseudovirus infectivity and particle associated envelope
glycoprotein. Western blots were scanned to determine gp120 and p24 band intensities
(INT×mm2) for the various pseudovirus stocks (since uncleaved gp160 does not confer
virus entry, only gp120 was scanned). Infectious pseudovirus titers (y-axis; IU/ng p24)
were plotted against virion-associated gp120 (x-axis; gp120 INT×mm2/p24
INT×mm2) and subjected to linear regression analysis. Correlation co-efﬁcient and p
value are shown.
Fig. 7. Expression of a Rev1–Vpu protein from fusion gene-containing Env cassettes.
Lysates of 293T cells transfected with the indicated Env expression vectors and
ZM247Fv1rev were probed with anti-Vpu and anti-gp120 antibodies to assess viral
protein expression, as well as with anti-neomycin phosphotransferase II (NPTII)
antibodies to control for transfection efﬁciency. Mock-transfected cells were included
for control. The migration patterns of ZM246F and ZM247Fv1 derived Rev1–Vpu, Vpu,
gp160 and gp120 proteins are indicated on the left and right, respectively.
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presence and absence of a proviral backbone. Based on these data,
we considered two possible explanations: (i) the presence of an
open rev1–vpu reading frame suppressed downstream Env transla-
tion, or (ii) the expressed Rev1–Vpu protein exerted a dominant
negative effect by interfering with Rev.
The Rev1–Vpu fusion protein does not exert a dominant negative effect
To assess whether the Rev1–Vpu protein exerted a dominant
negative effect, we generated CMV promoter-driven expression
vectors that contained only the rev1–vpu portions of the ZM247Fv1,
ZM247Fv1-fs, ZM246F and ZM246F-fs rev–vpu–env cassettes (start-
ing at the initiation codon of rev and ending at the stop codon of
vpu). Two of these vectors contained a rev1–vpu fusion gene
(prev1vpuZM247Fv1, prev1vpuZM246F-fs), while the other two did
not (prev1vpuZM247Fv1-fs, prev1vpuZM246F). Each of these con-
structs was then co-transfected with two proviral clones
(pZM247Fv1 and pZM246F-10, respectively), and the infectivity of
the resulting virions was determined in JC53-BL cells. As shown in
Fig. 8, the infectious titers of ZM247Fv1 and ZM246F derived
particles were not reduced upon co-transfection with the two rev1–
vpu fusion gene-containing plasmids (lanes 2, 5, 7 and 10). Thus,
there was no evidence that expression of the Rev1–Vpu protein in
trans interfered with Env glycoprotein biosynthesis. Interestingly,
cells transfected solely with the ZM247Fv1 IMC exhibited two bands
when probed with anti-Vpu antibodies. The predominant band
represented wildtype Vpu, while the fainter band represented the
Rev1–Vpu fusion protein (Fig. 8, lane 1). These data thus indicated
that the Rev1–Vpu fusion protein was not only expressed from rev–
vpu–env cassettes, but also from proviral genomes, albeit at much
lower levels.
Fig. 8. Lack of a Rev1–Vpu mediated dominant negative effect. Infectious titers of
virions derived by cotransfection of IMCs (ZM247Fv1, left panel; ZM246F, right panel)
and the various rev1–vpu expression vectors (labeled on the bottom) are graphed
relative to the infectious titer obtained for the corresponding IMC alone (set as 1).
Immunoblots of corresponding cell lysates depicting relative amounts of expressed Env
(gp160/gp120), Gag (p24), Rev1–Vpu and Vpu proteins are shown below. Infectious
titers were averaged from two different experiments (mean and standard error are
shown).
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complementation defect
To examine the generality of our ﬁndings, we tested the biological
activity of 8 additional transmitted/founder Env expression cassettes,
all of which were derived from patients with acute and early HIV-1
subtype C infection (Abrahams et al., 2009). As shown in Fig. 9A, four
of these Env cassettes contained a rev1–vpu fusion gene
(703010200_E5, 1394C9_G1, 706010164_1A7, 1086_B2), while the
other four exhibited the more common gene arrangement of
separated rev1 and vpu genes (704809221_1B3, 2010_F5,
703010054_2A2, 703010217_B6). Fig. 9B illustrates the infectivity of
the respective pseudovirion stocks relative to that of ZM246F. All Env
cassettes that encoded a rev1–vpu fusion gene generated pseudovir-
ions that were poorly infectious, exhibiting titers that were 6- to 110-
fold lower than that of the ZM246F Env control (orange bars, left
panel). In contrast, all Env cassettes that encoded rev1 and vpu in
different reading frames (704809221_1B3, 703010054_2A2) or
separated by a translational stop codon (2010_F5, 703010217_B6)
generated pseudovirions that mediated efﬁcient cell entry similar to
the ZM246F Env control (orange bars, right panel). A single nucleotide
deletion in the intergenic region between rev1 and vpu restored the
function of all fusion gene-containing cassettes (blue bars, left panel).
Conversely, placement of a fusion gene into two functional env
constructs had the opposite effect (blue bars, right panel). These data
demonstrated that the rev1–vpu fusion gene caused a universally
defective Env phenotype.
Since a considerable fraction of subtype C viruses harbored the
rev1–vpu polymorphism, we searched for a practical solution to
repair the associated Env defect without having to resort to site-
directed mutagenesis. As shown in Fig. 6, elimination of the rev
initiation codon restored the biological activity of the ZM247Fv1 Envconstruct. Since the proviral backbone provides a functional Rev
protein, we reasoned that mutating the rev initiation codon in Env
cassettes should not abolish their function in the pseudotyping assay.
To test this hypothesis, we introduced a substitution into the forward
primer used to amplify the rev–vpu–env cassette that abrogated
translation initiation at the rev initiation codon (AUG to AUA). All
newly derived transmitted/founder Env cassettes (as well as
ZM247Fv1 and ZM246F) were reampliﬁed using this modiﬁed primer,
sequenced to ensure that they contained the desired mutation, and
tested in the pseudotyping assay. As shown in Fig. 9B, elimination of
the rev initiation codon restored the infectivity of all defective Env
cassettes (green bars, left panel), but left the biological activity of
functional Env cassettes intact (green bars, right panel). Thus,
abrogating rev translation in Env cassettes via PCR mutagenesis
represents a simple approach to repair the rev1–vpu mediated
pseudotyping defect.
Discussion
Previous studies have demonstrated that transmitted/founder
env genes express fully functional glycoproteins, consistent with the
fact that they are derived from viruses that are capable of crossing
the genital mucosa and establishing a productive infection (Keele et
al., 2008; Salazar-Gonzalez et al., 2009). Our initial ﬁnding of two
transmitted/founder Envs that were defective in the pseudotyping
assay (Fig. 1B) seemed to be at odds with this hypothesis. However,
concomitant analysis of their cognate proviruses (Fig. 1C) indicated
that the defect was not due to a dysfunctional env gene, but had its
roots in the pseudotyping assay. Since pseudotyping is widely used
to assess Env function, it was important to investigate the
underlying mechanism. Inspection of the various Env cassettes
revealed an unusual polymorphism upstream of the env gene in the
region between rev1 and vpu. In all phenotypically defective
constructs, the ﬁrst exon of rev and vpu were in the same reading
frame, without an intervening stop codon. In contrast, in all
functionally competent constructs, rev and vpu were in different
reading frames or separated by an in-frame stop codon. We used
site-directed mutagenesis to test this association and established a
causal link between gene arrangement and biological phenotype
(Figs. 3, 5 and 6): In all instances of phenotypic defectiveness, a
rev1–vpu fusion gene was present and associated with impaired
Env glycoprotein expression (Figs. 6 and 9).
Since the rev1–vpu polymorphism seemed to reduce Env expres-
sion solely from subgenomic vectors, we ﬁrst examined the
transcriptional proﬁle of fusion gene containing and wild-type Env
cassettes. Previous studies had shown that HIV-1 env pre-mRNAs are
inherently unstable in the absence of a splice donor site (SD4) that
forms a duplex with a small nuclear RNA (U1 snRNA) (Lu et al., 1990;
Kammler et al., 2001; Freund et al., 2003). Although this splice donor
was unaltered in all fusion gene containing Env cassettes (underlined
in Fig. 5), we speculated that its protective function might be
weakened by upstream vector sequences. As shown in Fig. 4, this
was not the case. Both fusion gene containing and wildtype Env
cassettes expressed similar amounts of rev–vpu–env transcripts at
steady state. Moreover, there was no evidence that the polymorphism
inﬂuenced the utilization of the SD4 splice site and shifted the balance
from full-length to spliced messages. Finally, we asked whether
phenotypically defective Env cassettes expressed a Rev1–Vpu fusion
protein andwhether this protein interfered with normal Rev function.
Although Rev1–Vpu was produced from all fusion gene-containing
constructs, there was no evidence that this protein exerted a trans-
dominant negative effect (Fig. 8). Since the phenotypic defect was
always observed when Rev1–Vpu and Env were expressed from the
same transcript, it seemed most likely that the presence of a large
upstream reading frame suppressed downstream Env translation
initiation.
Fig. 9. Repair of the rev1–vpumediated trans complementation defect by PCR mutagenesis. (A) Nucleotide and deduced amino acid sequences of the intergenic region between rev1
(blue) and vpu (green) are shown for eight additional subtype C transmitted/founder Envs. Dashes represent gaps introduced to optimize the alignment. The rev intron splice donor
SD4 is underlined. A schematic representation of the rev1 and vpu gene arrangement is shown on the right, with asterisks denoting in-frame stop codons. (B) Infectious titers of
pseudoviruses complemented with wildtype (orange) as well as frame shift (blue) and rev initiation codonmutated (green) Env cassettes are graphed relative to that of ZM246F Env
(set to 1). Infectious titers were averaged from at least three different experiments (mean and standard error are shown).
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requires bypassing of upstream rev and vpu initiation codons. This
involves one or more translational control mechanisms, including
ribosomal reinitiation, context-dependent leaky scanning and/or
ribosomal shunting (Kozak, 1987; Schwartz et al., 1990; Gale et al.,
2000). Ribosomes reinitiate translation at internal AUG codons after
their 40 S subunit pauses at a termination codon; efﬁcient
reinitiation requires that the upstream open reading frame is
short, and the downstream cistron is sufﬁciently distant to allow
re-loading of the 40 S subunit (Kozak, 1987; Kozak, 1999;
Luukkonen et al., 1995; Gale et al., 2000). Leaky scanning occurs
when the 40 S ribosomal subunit bypasses an AUG that deviates
from a strong initiation consensus (5′-GCCRCCAUGG-3′) (Kozak,
1987). Finally, ribosomal shunting involves the physical transloca-
tion of ribosomes to initiate translation at a downstream cistron
(Gale et al., 2000). Although all of these mechanisms have been
implicated in the translational control of HIV-1 proviral geneexpression (Schwartz et al., 1990; Luukkonen et al., 1995; Anderson
et al., 2007; Krummheuer et al., 2007), their relative contribution to
Env translation from polycistronic rev–vpu–env transcripts remains
unknown. Nonetheless, the rev1–vpu fusion gene interferes with at
least one of these mechanisms: Since its reading frame extends
beyond the Env AUG codon (Fig. 3A), ribosomal reinitiation after
translation that started at the rev AUG cannot occur. It is thus
possible that the reduction of Env expression from fusion gene
containing transcripts is due, at least in part, to the lack of a suitable
stop codon that promotes ribosomal reinitiation at the env AUG
codon. The fact that both frameshift and stop codons introduced by
mutagenesis restored Env expression (Fig. 6) is consistent with this
explanation. However, we cannot rule out that these same
mutations altered as yet unrecognized determinants in the mRNA
secondary structure that independently enhanced translation initi-
ation at the env AUG codon. Moreover, the fact that abrogation of
the Vpu initiation codon within an otherwise intact rev1–vpu cistron
354 M.H. Kraus et al. / Virology 397 (2010) 346–357restored Env expression at least partially (Fig. 6A, lane 6) suggests
the involvement of additional translational control mechanisms.
If the rev1–vpu fusion gene reduces the efﬁciency of Env
translation initiation from vector-derived transcripts, why is the
same not occurring in virally infected cells? In HIV-1 replication, the
great majority of env mRNAs (∼90%) are bicistronic, i.e., contain only
the vpu and env reading frames, because they are spliced at an
acceptor site (SA5) downstream of the rev initiation codon (Purcell
and Martin, 1993; Schwartz et al., 1990). Only ∼10% of env transcripts
utilize alternative splice acceptors (e.g., SA4c, b and a) that are located
upstream of the rev AUG codon (Purcell and Martin, 1993). Given this
pattern of env expression, mRNAs containing an intact rev1–vpu
reading frame would be expected to be rare in virally infected cells.
Consistent with this, we detected only a very small amount of Rev1–
Vpu protein in ZM247Fv1 transfected cells (Fig. 8).
To estimate the frequency of the rev1–vpu polymorphism in
naturally occurring strains of HIV-1, we inspected the arrangement of
these genes in over 1,700 HIV-1 sequences from the Los Alamos HIV
Sequence Database (http://www.hiv.lanl.gov/). This analysis showed
that all members of HIV-1 subtypes B, D, F, G, H, K, and J (n=870), the
great majority of circulating recombinant forms (CRFs) (n=163), as
well as all members of HIV-1 groups N, O and P (n=48) encoded rev1
and vpu in different reading frames or separated by stop codons.
However, 3% of subtype A (4/132) and 20% of subtype C (82/429)
viruses, as well as 5% of CRF01_A/E strains (7/148), had rev1 and vpu
in the same uninterrupted reading frame. The fusion gene was also
found in C/D and B/C mosaics, indicating that the polymorphism can
be passed by recombination. Thus, a substantial fraction of subtype A
and C Envs (and their recombinants) have likely eluded biological
characterization in the past because they appeared defective in the
pseudotyping assay.
To eliminate this potential bias, we designed a PCR strategy that
would generate functional Env cassettes regardless of the upstream
gene arrangement. For this, we took advantage of the observation that
the biological activity of the fusion gene-containing ZM247Fv1
Env cassette could be repaired by abrogating translation at its rev
initiation codon (Fig. 6A, lane 5). We found that PCR re-ampliﬁcation
with a primer that introduced a missense mutation into the rev
initiation codon rendered all phenotypically defective Env cassettes
functional, while leaving the biological activity of all functional Env
cassettes intact (Fig. 9). It should be noted that we also attempted
to repair the rev1–vpu-mediated defect by expressing the env gene in
the absence of upstream rev and vpu sequences. We examined this
strategy in light of a recent report contending that upstream rev
sequences are dispensable for Env trans complementation (Beels
et al., 2008). Using a ZM247Fv1 env expression vector that lacked all
upstream rev1 and non-overlapping vpu sequences, we failed to
generate infectious pseudovirions (not shown). These results are
consistent with other studies showing that env transcripts require
both the SD4 splice donor as well as upstream guanosine-adenosine-
rich (GAR) splicing enhancers for stability (Lu et al., 1990; Kammler
et al., 2001; Freund et al., 2003; Asang et al., 2008). The fact that these
sequence motifs are all located within the ﬁrst exon of rev and the rev
intron explains why inclusion of these sequences into the rev–vpu–
env expression cassette increases Env production and pseudovirion
infectivity.
In summary, we report here that a subset of HIV-1 subtype A and C
viruses exhibit an atypical genome organization in having the ﬁrst
exon of rev and vpu in the same reading frame without an intervening
stop codon. This gene arrangement does not impact the replication
competence of HIV-1 in vivo, but does adversely affect Env expression
from subgenomic rev–vpu–env transcripts in vitro. If unrecognized,
this can cause problems in studies that require Env trans comple-
mentation, such as the analysis of HIV-1 entry and neutralization
properties. However, we have devised a solution to this problem by
mutating the rev initiation codon in the forward PCR primer used toamplify the rev–vpu–env cassettes. Our studies also emphasize the
unique value of transmitted/founder viruses as reagents for investi-
gating HIV-1 biology and transmission. Since these viruses must
exhibit a high degree of replication ﬁtness, in vitro results that suggest
otherwise must be investigated. Cases of “phenotypic defectiveness”
of transmitted/founder viruses, such as the Env complementation
defect reported here, are unlikely to be the result of dysfunctional
genes. Rather, they are likely an indicator of a novel viral phenotype
that has previously gone unrecognized.
Materials and methods
Molecular cloning of transmitted/founder Env cassettes
Full-length rev–vpu–env cassettes were ampliﬁed from plasma
viral RNA of subjects acutely infected with HIV-1 subtype C using
single genome ampliﬁcation (SGA) methods as described (Salazar-
Gonzalez et al., 2008; Abrahams et al., 2009). Amplicons were
sequenced directly and used to infer the transmitted/founder env
sequences (Salazar-Gonzalez et al., 2008; Abrahams et al., 2009). SGA
amplicons that matched these transmitted/founder env sequences
were selected for cloning using the pcDNA 3.1 Directional Topo
Expression Kit (Invitrogen). In this system, four bases are added to the
forward primer (CACC), and a complementary single-strand overhang
in the plasmid vector (GTGG) permits the directional cloning of blunt-
ended PCR products in the sense orientation. To utilize this system for
the cloning of transmitted/founder Envs, we used a modiﬁed
(underlined) second round forward primer (5′-CACCGGCTTAGGCAT-
CTCCTATGGCAGGAAGAA-3) together with the corresponding reverse
primer (5′- CTGCCAATCAGGGAAGTAGCCTTGTGT-3′) to reamplify ﬁrst
round SGA ampliﬁcation products. The resulting amplicons were then
cloned into pcDNA 3.1 under the transcriptional control of the
cytomegalovirus (CMV) immediate early promoter/enhancer. All molec-
ularly cloned rev–vpu–env cassettes were sequenced in their entirety to
ensure that they matched the corresponding transmitted/founder
sequences.
Construction of an Env-deﬁcient subtype C backbone vector
To generate an Env-deﬁcient subtype C proviral backbone, we
abrogated Env translation from the pZM247Fv1 infectious molecular
clone (IMC) by placing a nonsensemutation into the env open reading
frame immediately downstream of vpu, followed by a single base pair
deletion. This was accomplished by cleaving pZM247Fv1 with BaeI
and removing an internal 28 bp fragment. This fragment was then
replaced with a synthetic adapter that contained the desired
mutations as well as cohesive ends complementary to BaeI-cleaved
vector ends. The adapter was generated by annealing two oligonu-
cleotides 5′-ATTAGGGGG_ACCTGTGTGGAAAGAAGCAAAAA-3′ and 5′-
GCTTCTTTCCACACAGGT_CCCCCTAATAGACT-3′ (mutations are under-
lined). BaeI-cleaved pZM247Fv1 plasmid DNA (50 ng) was incubated
with both oligonucleotides in 10 μl Klenow buffer at 60 °C for
15 min, followed by an incubation of 30 min at room temperature to
facilitate annealing of oligonucleotides and cohesive ends. The
reaction was then adjusted to 1× ligation buffer and ligated at 15 °C
in the presence of 5U DNA ligase (Roche) for 15 h in 20 μl. The
resulting ZM247FΔEnv mutant clone was conﬁrmed to have the
desired mutations by sequence analysis of the entire proviral DNA.
This subtype C speciﬁc backbone vector has been submitted to the
National Institute of Health AIDS Research and Reference Reagent
Program.
Site-directed mutagenesis of Env expression cassettes
In vitromutagenesis was conducted using the QuikChange II XL site-
directed mutagenesis kit as described (Stratagene). Cycling conditions
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denaturation at 95 °C, 50 s annealing at 50–60 °C, 9 min polymerization
at 68 °C and ﬁnal 15 min extension at 68 °C. After equilibration at 4 °C,
original template and hemimethylated plasmid DNAwere cleavedwith
10U of DpnI at 37 °C for 2 h. XL10-Gold or XL2-MRF (Stratagene)
competent bacteriawere transformedwith 1 μl of unmethylated, nicked
circular mutant plasmid DNA. The following mutagenic primers were
used (substitutions are bold faced, deletions are indicated by a gap,
insertions are shown in lower case): ZM247Fv1-fs (5′-AGCAGTAAG-
TACCAA_TAGTAGATGTAATGC-3′); ZM247Fv1-stop (5′- GTATCAAA-
GCAGTAAGTACTAAATAGTAGATGTAATGC-3′); ZM247Fv1-Rev– (5′-
TTAGGCATCTCCTATAGCAGGAAGAAGCGG-3′); ZM247Fv1-Vpu− (5′-
GTACCAATAGTAGATGTAATACTTGAATTAGATTATAAAATAGC-3′);
ZM246F-fs (5′-GCAGTAAGTATCTGaTAATGGTGGATTTA-3′);
703010200E5-fs (5′-TCAAAGCAGTAAGTACTCA_TAGTAGATGTG-3′);
1394C9G1-fs (5′-AAGCAGTAAGTACCCA_TAGTAGATGTAATG-3′);
7060101641A7-fs (5′- ATATCAAAGCAGTAAGTACAAA_TAGTAGATG-
TAATGGTAGAC-3′); 1086B2-fs (5′- TATCAGAGCAGTAAGTACTCA_ TAG-
TAGATGTAATGATAGA-3 ′ ) ; and 7048092211B3- f s (5 ′ -
CTCTTATATCAAAGCAGTAAGTATgATGTAATGCTAAGTTTAATAG-3′).
The ZM247Fv1-Rev−Vpu− double mutant was generated by substitu-
tion of the rev initiation codon in the ZM247Fv1-Vpu− mutant. For
ZM247Fv1, ZM246F, 703010200_E5, 1394C9_G1, 706010164_1A7,
1086_B2, 704809221_1B3, 2010_F5, 703010054_2A2, and 703010217_
B6, the rev initiation codon was eliminated by re-ampliﬁcation with a
modiﬁed forward primer that altered the rev initiation codon (5′-
CACCGGCTTAGGCATCTCCTATAGCAGGAAGAA-3′). Amplicons were
cloned into pcDNA 3.1 Directional TOPO as described above. All site-
directed mutants were sequenced in their entirety to conﬁrm the
presence of the desired mutations and the absence of PCR-introduced
errors.
Construction of rev and rev1–vpu eukaryotic expression vectors
To generate a rev expression vector (pcDNA247Frev), we synthe-
sized the coding sequence of ZM247Fv1 rev exons 1 and 2 (Blue Heron
Biotechnology) and directionally cloned the fragment into pcDNA3.1
Directional TOPO (Invitrogen). To generate rev1-vpu expression vectors
(prev1vpuZM247Fv1, prev1vpuZM247Fv1-fs, prev1vpuZM246F and
prev1vpuZM246F-fs), we used Phusion Hot-Start polymerase (New
England Biolabs) and the following primers (ZM247Fv1 and ZM246F
forward 5’- actttctagatacaaTATGGCAGGAAGAAGCGGAGACA-3’, reverse
ZM247Fv1 5’- aagaacgcgTTATAAGTCAATAGCACCCAAAAGCCTAA-
TATGCC-3’; reverse ZM246F 5’- aagaacgcgtCTATAAATCATCAAAAAGCC-
TAATATGCTCCATATCCA-3’) to amplify the corresponding region from
the ZM247Fv1, ZM247Fv1-fs, ZM246F and ZM246F-fs rev-vpu-env
cassettes. Unique XbaI and MluI sites in the primers sequences
(underlined) facilitated directional cloning into pCG-IRES-eGFP (kindly
provided by Frank Kirchhoff). All constructs were sequence conﬁrmed.
Northern blot analysis
293T cells were transfected with ZM247Fv1 and ZM247Fv1-fs Env
cassettes (4 μg) alone or with pcDNAZM247Fv1rev (4 μg) using the
liposomal FuGene6 transfection reagent (Roche). 72 hours following
transfection, total cellular RNAwas extractedwith phenol/chloroform
using the RNA STAT-60 reagent (Tel-Test). For electrophoresis, 15 μl
loading buffer (50% formamide, 6% formaldehyde, 1× MOPS, 10%
glycerol, 0.013% bromophenol blue) were added to 1 μg total RNA in
5 μl water. RNA was denatured at 65 °C for 10 min, chilled on ice for
1 min and electrophoresed at 60 V for 4 h in 1% denaturing agarose
gels (1× MOPS, 2% formaldehyde) using 1× MOPS running buffer
(20 mMMOPS, 5 mM sodium acetate, 2 mM EDTA). Gels were stained
with 0.25 μg/ml ethidium bromide to assess RNA integrity by the
relative intensity of 18 S and 28 S ribosomal RNA. Gels were rinsed
twice 15 min in 20× SSC (0.3 M sodium citrate, 3 M NaCl), and RNAwas blotted by capillary transfer in 20× SSC for 15 h to positively
charged nylonmembranes (Roche). Following RNA immobilization by
UV-crosslinking (125 ml), the ﬁlter was rinsed in water and air-dried.
For simultaneous detection of unspliced and spliced transcripts, a
∼300 nt antisense cRNA hybridization probe encompassing the
second exon of the ZM247Fv1 rev was synthesized by run-off
transcription. For this, the DNA template was generated by PCR
using Phusion Hot-Start polymerase (New England Biolabs) and the
following primers (forward 5′-aattaaccctcactaaagggCATTTCAGACCC-
TTATCCCAAACTCG-3′, reverse 5′-taatacgactcactatagggCCCAGATACT-
TAAGGATTTGCCACCC-3′) and 10 ng of ZM247Fv1 Env plasmid DNA.
RNA polymerase promoters T3 or T7 (underlined in primer
sequences) were incorporated at the 5′ end of sense and antisense
primer, respectively. PCR conditions included 30 s template denatur-
ation at 98 °C, followed by 25 cycles denaturation at 98 °C (10 s),
annealing and polymerization at 72 °C (45 s) and a ﬁnal extension of
15 min at 72 °C. The 305 bp ampliﬁcation product was gel puriﬁed. A
commercial digoxigenin Northern kit (Roche) was used for cRNA
probe synthesis, hybridization and chemiluminescent detection.
Immunodetection of hybridized probe by alkaline phosphatase-
coupled anti-digoxigenin antibody and visualization by chemilumi-
nescent CDP-Star substrate were performed according to manufac-
turer's speciﬁcation (Roche).
Generation of viral stocks
Viral stocks were generated by transfection of 293T cells with (i)
proviral constructs (IMCs) or (ii) subtype B (SG3Δenv) or subtype C
(ZM247Fv1Δenv) backbone vectors in combination with Env expres-
sion cassettes. Single-round infectivity of the resulting viruses was
tested in JC53-BL (TZM-bl) cells, a HeLa-derived cell line that
constitutively expresses cell surface receptors CD4, CCR5 and CXCR4
for virus entry. JC53-BL cells also contain luciferase and beta-gal
reporter genes under the control of an HIV-1 LTR, facilitating
quantitative assessment of virus entry over a broad infectivity range
(Derdeyn et al., 2000; Wei et al., 2002; Wei et al., 2003). JC53-BL cells
were seeded in 24-well plates at a density of 50,000 cells/well in
Dulbecco's modiﬁed Eagle medium (DMEM) containing 10% fetal calf
serum (FCS). Serial dilutions of 293T transfection-derived virus stocks
were added in a ﬁnal volume of 250 μl/well containing 40 μg/ml
DEAE-dextran (Sigma). Fourty-eight hours post-infection, plates were
stained, and beta-galactosidase-positive cells were counted. Virion
infectivity was standardized as infectious units (IU) per ng of p24
antigen in the culture supernatant. Replication competence of IMCs
was assessed in primary human CD4+ T cells as described (Salazar-
Gonzalez et al., 2009).
Immunoblot analysis
The protein content of Env-pseudotyped virions and corresponding
cell lysates was examined by Western blot analysis, using anti-HIV-1
Gag- and Env-speciﬁc antibodies or HIV-1 subtype C donor plasma.
Expression of Vpu and Rev1–Vpu was assessed in 293T cell lysates
using a subtype C anti-Vpu rabbit antiserum. Cell-free supernatants
were pelleted at 40,000×g and 4 °C for 1 h, and virus pellets
solubilized in a buffer containing 50 mM Tris pH 7.8, 80 mM KCl,
2.5 mM dithiothreitol (DTT), 0.75 mM EDTA and 0.5% Triton X-100.
Virion associated reverse transcriptase (RT) activity was measured
using a colorimetric enzyme-linked immunosorbent assay as previ-
ously described (Takehisa et al., 2007) and used to equilibrate protein
loading. For protein analysis of cell lysates, cells were lysed in StaphA
buffer (25 mM sodium phosphate pH 7.4, 100 mM NaCl, 1% Triton X-
100, 0.1% sodium dodecyl sulfate, 0.5% deoxycholate, 5 mM EGTA)
containing 1 mM phenylmethylsulfonyl ﬂuoride and 10 μg/ml
aprotinin protease inhibitors, and the protein concentration was
determined using the bicinchoninic acid reagent (Pierce). Viral
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were separated under denaturing electrophoresis conditions on 4 to 12%
precast Bis-Tris polyacrylamide gradient gels (Invitrogen) and trans-
ferred to polyvinylidene diﬂuoride membranes (Millipore). Electropho-
resis of Vpu proteins was performed using 12% precast Bis-Tris gels.
Membrane blocking and antibody treatment were conducted in Tris-
buffered saline, pH 7.5 (TBS) containing 0.05% Tween 20 and 5% non-fat
dry milk. Binding of primary antibodies was visualized with horseradish
peroxidase-conjugated anti-IgG (H+L) secondary antibodies (Pierce),
followed by West Femto chemiluminescence detection (Pierce). Poly-
clonal anti-p24 rabbit antiserum (NIH AIDS Research and Reference
Reagent Program #4250) was used at a dilution of 1:100,000. A
polyclonal anti-gp120 antibody (H6001-15; US Biologicals) and heat-
inactivated plasma from a patient chronically infected with HIV-1
subtype Cwere used at a dilution of 1:1,000. A polyclonal rabbit antibody
against neomycin phosphotransferase II (Millipore) was used at a
concentration of 100 ng/ml.
Regression analysis of Env gp120 incorporation and infectivity of
pseudovirions
To quantitate virion-associated gp120, short ﬁlm exposures of
anti-gp120 and anti-p24 immunoblots were scanned using a Biorad
ChemiDoc XRS Imager. The area of individual gp120 and p24 bands
was integrated (INT×mm2) and adjusted by global background
subtraction employing Quantity One software version 4.6.3
(Biorad). To assess virion-associated gp120 content, the ratio of
corresponding gp120 and p24 values was determined (Env gp120
INT×mm2/p24 INT×mm2). Virion-associated gp120 content and
viral infectivity (IU/ng p24) of individual wildtype and mutant
pseudovirions was graphed and subjected to linear regression
analysis using Prism GraphPad software 4.0C. The signiﬁcance of
the correlation was evaluated by the square of the Pearson
correlation coefﬁcient (R2) and the two-tailed p value for a 95%
conﬁdence interval.
Generation of anti-Vpu antibodies speciﬁc for HIV-1 subtype C
The cytoplasmic domain of the ZM247Fv1 vpu gene (codons 30 to
82) was PCR ampliﬁed and cloned downstream and in frame with
glutathione-S-transferase (GST) into pGEX-3X (GE Healthcare).
Escherichia coli BL21 (DE3) Rosetta cells (Novagen) were transformed
with the resulting plasmid and single colonies were expanded in LB
broth containing 100 μg/ml ampicillin and 12.5 μg/ml chloramphen-
icol at 37 °C. When cultures reached a density of OD600=0.8,
expression of the fusion protein was induced for 3 hours by addition
of 0.5 mM isopropyl beta-D-1-thiogalactopyranoside (IPTG). Follow-
ing lysis of the bacterial pellet by sonication in phosphate-buffered
saline (PBS), the GST–Vpu fusion protein was extracted from the
insoluble fraction in a buffer containing 20 mM Tris–HCl pH 7.9,
500 mM NaCl, 1 M imidazole, and 6 M urea. For puriﬁcation, the
solution was gradually diluted to 0.75 M urea, PBS (pH 7.4), 500 mM
NaCl, 0.1% Triton X-100, and insoluble matter was removed by
centrifugation. Renatured protein was allowed to bind to glutathione
agarose and after successive washes with PBS (pH 7.4), 500 mM NaCl,
0.1% Triton X-100 and PBS (pH 7.4), 150 mM NaCl, 0.1% Triton X-100,
respectively, the puriﬁed GST–Vpu fusion protein was eluted in a
buffer containing 10 mM glutathione, 50 mM Tris pH 8.0, and 150mM
NaCl. Rabbits (n=2) were immunized with 200 μg GST–Vpu fusion
protein mixed with Complete Freund's Adjuvant and boosted at
weeks 2, 3, 7 and 11 with 100 μg fusion protein mixed with
Incomplete Freund's Adjuvant (Cocalico Biologicals). Immune sera
were collected following the third and ﬁnal boost and used at a
dilution of 1:5000 for Western blot analysis. The anti-Vpu antiserum
has been submitted to the National Institute of Health AIDS Research
and Reference Reagent Program.Acknowledgments
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